banner

 

DAVID P. HESSON, PhD

484-319-5938 (mobile)
610-889-0747 (FAX
)
dphesson@comcast.net

 

EDUCATION


Visiting Scholar, University of Pennsylvania, School of Medicine; Dr. Mark Greene,                                              2012-present

Post Doctoral, Chemistry, National Institutes of Health Fellow, Harvard University;          
                         Dr. R. B. Woodward (deceased), 1976-1978

Ph.D., Chemistry, Massachusetts Institute of Technology; Dr. J. E. Baldwin, 1972-1976


B.S., Chemistry, University of Michigan, Ann Arbor, Michigan; Dr. J. P. Marino, 1968–1972

 

PROFESSIONAL EXPERIENCE

 

LytPhage, INC.

President and Founder                                                                                     2015-present     LytPhage is a start up biotech company developing novel therapeutics for the treatment of anitbiotic resistant infections. We are developing genetically engineered bacteria viruses (bacteriophage) to safely treat life threatening bacterial infections with technology from the laboratory of Dr. Roy Stevens of Temple Univeristy. LytPhage is a Philadelpohia Science Center Phase 1 Ventures recipient.

 

RIBONOVA, INC.

Director Development and Founder                                                                 2012-2014     RiboNova is a start up pharmaceutical and diagnostic research company studying the role of transfer RNA in cancer and infectious diseases.  I head the chemistry and development efforts of the company.

UNIVERSITY OF PENNSYLVANIA MEDICAL SCHOOL

Visiting Scholar                                                                                                  2012-present     I am working in the laboratory of Professor Mark I. Greene to provide drug development strategy and medicinal chemistry support of on going research projects.  The laboratory is searching for small molecule therapeutics in the cancer and inflammatory disease areas.

DP HESSON CONSULTING

President                                                                                                            2012-present
I provide research planning and CMC drug development advice for early stage pharmaceutical and biotech start-ups.

  • I am working with Corridor Pharmaceuticals to develop and finance the small molecule Arginase I/II inhibitor into the clinic for serious fibrotic pulmonary diseases.
  • Work with Philadelphia University City Science Center QED Program on three programs as a research and business advisor for cancer, autoimmune, and inflammatory diseases with teams at University of Delaware, Thomas Jefferson University, CHOP and Penn.
  • Consultant to Biostrategy Partners for potential acute myelogenous leukemia start-up companies.      

PROMEDIOR, INC.

VP Product Development                                                                                      2006-2009
Promedior is a start up (March 2006) therapeutic biotech company developing drugs for the treatment of fibrotic diseases.  I was responsible for planning, building, and managing the pharmaceutical development portion of Promedior.  I also managed the IP portfolio.

  • Hired a 10 person development team including pharmacology, clinical biomarkers, safety/toxicology and biopharmaceutical manufacturing in 9 months. Developed from DNA via CMO’s the cloning, expression and cGMP manufacture of 125 kDa protein in 15 months.
  • Developed preclinical pharmacology programs with 8 leading academic fibrosis research groups.
  • Completed the execution in 2 years of a preclinical pharmacology, toxicology and CMC data necessary to file the IND submission of PRM-151 a recombinant human protein.

GPC BIOTECH, INC.


Worldwide Director of Project Management & In-Licensing                                   2003-2006
GPC Biotech was an oncology based R&D company developing Phase I, II and III drugs for cancer therapy.  I planned and coordinated all parts of development-phase projects from preclinical to commercial launch.  I helped business development evaluate and rank potential in-licensing candidates.  I was a member of the due diligence team providing background for prospective partners. 

  • Planned and executed the satraplatin worldwide Phase III satraplatin pivotal trial and US & EU regulator filings.
  • Organized satraplatin rolling NDA submission and European EMEA filings.
  • Planned two small molecule CDK antagonists and one in-licensed pre-clinical to Phase I US projects.
  • Planned and executed the antibody 1D09C3 preclinical to Phase I European project.
  • Supported partnering negotiations with Pharmion 2005 and other ongoing partnership opportunities.

NEURON THERAPEUTICS, INC

Director Drug Product Development                                                                  1999-2003
Neuron Therapeutics was a neuroscience based start-up developing a drug device combination for the treatment of stroke and sub-arachnoid hemorrhage.  I planned and implemented all of the activities necessary for the development of the drug portion of the Neuron perfusion therapy system.    I managed all of the CMC internal and contract development of the perfusion drug product.   I supported clinical and pharmacy development.   I managed the intellectual property portfolio.  Note: Neuron ended operations in November of 2002.

  • Wrote the 3 CMC sections for successful IND filings in 2000-2002 and one European BfArM 2001.
  • Managed the API and drug product manufacture for preclinical/clinical supplies for US and Europe.
  • Authored and filed 7 patents in 2000-2002.

OREAD,INC

Director Program Management                                                                           1997-1999
Oread was a CMC/Toxicology contract research organization.  I planned and implemented pharmaceutical drug development programs for Oread clients.  I managed programs across multiple sites for all aspects of preclinical, clinical packaging and manufacturing of drug in development and marketed compounds.  Oread was the first full service contract drug development company.  Note: Oread entered Chapter 11 bankruptcy proceedings in 2001.

  • Implemented a $1.2 M Phase II/III/Commercial formulation development program for a major pharmaceutical company.
  • Completed a synthesis and tablet formulation development project for a small pharmaceutical company.
  • Designed and initiated two IND enabling oncology programs for two medium size biotech companies.

SYMPHONY PHARMACEUTICALS

Director, Medicinal Chemistry                                                                        1993-1997
I developed and directed the research for the drug discovery effort of Symphony Pharmaceuticals, a start-up pharmaceutical effort to discover and develop proprietary drugs that regulate ion flow and normalize brain and body function to treat neurological and neurodegenerative disorders.  The efforts were concentrated on glutamate excitatory amino acid receptors.

  • Established 10 new Ph.D. chemists as start-up research staff within 18 months.  Designed, built and equipped new research facility and developed laboratory procedures and policies. 
  • Lead research team in discovery of new AMPA receptor antagonist with patent filing June 7, 1995 and discovery of kainate receptor antagonist resulting in 1 patent, 5 publications, and 8 abstracts.

DU PONT/DU PONT MERCK PHARMACEUTICALS (1978-1993)

Director, Intellectual Property Management                                                          1992-1993
I directed a group within R&D that was responsible for patent liaison, grant, contract and publication administration.  The major efforts of this group were patent preparation, strategy, the technical and scientific aspects of patent prosecution and patent portfolio management.

  • Redesigned patent portfolio organization improving decision making resulting in $250,000 additional saving in 1993.  Eliminated patent filing backlogs by 50% and decreased the average preparation time for all priority cases to 8-weeks.

Associate Medical Director, Oncology & Neurology                                               1990-1991
Developed the Phase II clinical trial strategy and design for anthrapyrazole cancer therapeutic agents.  This included arranging, monitoring trial progress and analysis of results for the DuP 937, 941, 942 Phase II programs.  Designed Phase III long-term safety and special efficacy studies for DuP 996, a drug for treatment of Alzheimer's related dementia.  This included protocol design and investigator arrangements. 

  • Prepared and executed a worldwide 7-tumor single protocol Phase II study which completed patient enrollment in 14-months.
  • While in the clinical group I also coordinated the Du Pont Merck Research Advisory Board and the Development Advisory Board.  I was also Program Manager for the Duke/Du Pont Research, 87-91.

Planning Manager, Life Science Technology, C.R. & D.                                        1988-1990
My office prepared comprehensive analysis and strategies for R&D within Du Pont.  I studied and analyzed current and future R&D budget plans.  I facilitated and coordinated the interdepartmental planning of technology related to agricultural, pharmaceutical and diagnostic research. 

  • Developed and taught a new strategic management of technology course to >250 Du Pont R&D managers which increased planning cooperation between business and research. Increased interdepartmental research awareness by chairing the annual Bioscience Forum for three years.
  • Improved critical review of pharmaceutical and diagnostics R&D programs by the Du Pont Life Science Research Advisory Board by increasing premeeting information preparation.

Research Manager, Du Pont Medical Products Department,                                  1986-1988
Coordinate the Medicinal Chemistry research programs for three disease areas; Antiinflammatory, Antimicrobial and Cancer disease and also the Medicinal Chemistry Synthesis Group.  During this time I continued my personal research in the Cancer Chemotherapy area that was related to phosphotidylinositol transmembrane signaling and applications of computer modeling to chemistry.  As part of our Cancer research, I was the liaison between the National Cancer Institute and Du Pont.  

  • Used new computer modeling techniques to discover a new class of Protein Kinase C inhibitors.
  • Coordinated the chemistry research and development of two new oxazolidinone antibiotics for clinical testing and for a new antifungal agent.
  • Discovered and led the preclinical development team for DuP 785, the first anticancer agent from Du Pont research.
  • Initiated program with the National Cancer Institute using computer searching to make Du Pont the largest single supplier of new compounds to the National Cancer Institutes sample program.

GRADUATE RESEARCH EXPERIENCE

Postdoctoral:  "Total Synthesis of Erythromycin” My work at Harvard was the general study of chemistry and approaches toward the synthesis of Erythromycin.


Graduate:  Thesis Title:  "Synthetic Applications to Antibiotics” My graduate work was the synthesis of novel penicillin and cephalosporin antibiotics

COMMUNITY WORK


When living in Delaware:  I was President of the Windybush Civic Association which represented 180 families in our neighborhood and I dealt with County and State Government and assisted with local problems.  Since 1985, I was a member and President (1989-1990) of the Council of Civic Organizations of Brandywine Hundred Zoning and Planning Committee.  I also coached a Brandywine Little League baseball team. When living in Pennsylvania:  I am currently President of the Wyckfield Homeowners Association, (1994 -present). I was a Board member and Treasurer of Paoli Legion Baseball (1994-2001).  I am currently Chairman of the East Whiteland Township Zoning Hearing Board (2000-present).

 

home | services | vitae | publications | patents